<span item_type="fundamental" item_id="1e89990ddf929af48466e9f675b5b677" counter_id="ST/US/AUPH" env="prod"></span><span item_type="announcement" item_id="645721005021399553" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 77.71 M, beating the estimate of USD 76.98 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD 0.25, beating the estimate of USD 0.195.</p><p>EBIT: As of FY2026 Q1, the actual value is USD 38.92 M.</p><p></p><p>Aurinia Pharmaceuticals Inc. (Aurinia 制药) reported its financial results for the quarter ended March 31, 2026. The actual financial and operational metrics were not directly presented within the text of the Form 8-K itself but were part of an attached press release <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/auph-20260507.htm"></span>.</p><h4>Total Revenue</h4><p>For the three months ended March 31, 2026, total revenue was $77.7 million, marking a 24% increase from $62.5 million in the same period of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p><h4>Net Product Sales</h4><p>Net product sales of LUPKYNIS reached $73.6 million for the three months ended March 31, 2026, which is a 23% increase from $60.0 million in the comparable period of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p><h4>License, Collaboration and Royalty Revenue</h4><p>License, collaboration and royalty revenue from Otsuka totaled $4.1 million for the three months ended March 31, 2026, representing a 64% rise from $2.5 million in the same period of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p><h4>Net Income</h4><p>Net income for the three months ended March 31, 2026, was $34.4 million, up 48% from $23.3 million in the same period of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p><h4>Operational Metrics (in thousands)</h4><ul><li><strong>Cost of revenue</strong>: $6,505 for the three months ended March 31, 2026, compared to $8,574 for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</li><li><strong>Selling, general and administrative</strong>: $22,029 for the three months ended March 31, 2026, compared to $20,339 for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</li><li><strong>Research and development</strong>: $7,470 for the three months ended March 31, 2026, compared to $5,743 for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</li><li><strong>Restructuring</strong>: $0 for the three months ended March 31, 2026, compared to $1,533 for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</li><li><strong>Other expense, net</strong>: $279 for the three months ended March 31, 2026, compared to $4,429 for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</li><li><strong>Total operating expenses</strong>: $36,283 for the three months ended March 31, 2026, compared to $40,618 for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</li><li><strong>Income from operations</strong>: $41,422 for the three months ended March 31, 2026, compared to $21,847 for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</li></ul><h4>Cash Flow from Operating Activities</h4><p>Cash flows from operating activities were $32.6 million for the three months ended March 31, 2026, a significant increase of 2408% from $1.3 million in the same period of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p><h4>Cash Position</h4><p>As of March 31, 2026, Aurinia 制药 held cash, cash equivalents, restricted cash, and investments totaling $378.8 million, a decrease from $398.0 million at December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p><h4>Cash Flows from Financing Activities</h4><p>Cash outflows from financing activities amounted to - $53.7 million for the three months ended March 31, 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>. This included the repurchase of 2.5 million common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p><h4>2026 Total Revenue and Net Product Sales Guidance</h4><p>Aurinia Pharmaceuticals Inc. reiterates its guidance for 2026 total revenue to be between $315 million and $325 million, representing an 11% to 15% increase compared to 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>. The company also projects 2026 net product sales to range from $305 million to $315 million, an anticipated increase of 12% to 16% over 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm"></span>.</p>

Aurinia Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 77.71 M